To include your compound in the COVID-19 Resource Center, submit it here.

Madrigal's MGL-3196 meets in Phase II NASH trial

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) reported top-line data showing that MGL-3196 (VIA-3196) met the primary endpoint in a Phase II trial to treat biopsy-proven non-alcoholic steatohepatitis (NASH).

On the 125-patient

Read the full 288 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE